Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13851460 | 0.84 | KMT2A (0.42) | ALDH1A1KMT2AAKR1C3AKR1C2CYP1A2 | |
| SCHEMBL6930628 | 0.82 | ADAM17 (0.64) | ALDH1A1MEN1KMT2ANPC1LMNA | |
| SCHEMBL6929115 | 0.81 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ANPC1LMNA | |
| SCHEMBL11097086 | 0.80 | LDHA (0.50) | LDHAALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL7312224 | 0.80 | ADAM17 (0.48) | ALDH1A1MEN1KMT2ANPC1LMNA | |
| SCHEMBL28949706 | 0.80 | BCAT2 (0.51) | ALDH1A1LMNASMN1; SMN2ADAM17CYP1A2 | |
| SCHEMBL12264556 | 0.79 | LDHA (0.46) | LDHAALDH1A1MEN1KMT2ANPC1 | |
| SCHEMBL1744968 | 0.78 | HTT (0.66) | LDHAALDH1A1KMT2ALMNARAB9A | |
| SCHEMBL6662240 | 0.76 | ADAM17 (0.75) | ADAM17MMP9MMP1MMP7MMP8 | |
| SCHEMBL25268462 | 0.76 | EPHX1 (0.55) | LDHAALDH1A1SMN1; SMN2AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4738738-B2 | — | — | 2011-08-03 | — | — | JP | claimed |
| EP-1576089-A4 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA CELL LTD (IL) | 2007-02-14 | — | — | EP | claimed |
| EP-1485464-A4 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA CELL LTD (IL) | 2006-11-29 | — | — | EP | claimed |
| JP-2005528088-A | — | — | 2005-09-22 | — | — | JP | claimed |
| EP-1576089-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | Gamida Cell Ltd. (IL) | 2005-09-21 | — | — | EP | claimed |
| EP-1485464-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | Gamida Cell Ltd. (IL) | 2004-12-15 | — | — | EP | claimed |
| WO-2003078567-A2 | METHODS OF INDUCING DIFFERENTIATION IN EX VIVO EXPANDED STEM CELLS | GAMIDA-CELL LTD. (IL) | 2003-09-25 | — | — | WO | claimed |
| WO-2003062369-A2 | EXPANSION OF RENEWABLE STEM CELL POPULATIONS | GAMIDA-CELL LTD. (IL) | 2003-07-31 | — | — | WO | claimed |
| EP-0970046-B1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH CORP (US) | 2003-12-10 | — | — | EP | disclosed |
| US-20020188120-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-12-12 | — | — | US | disclosed |
| US-6462073-B2 | METALLOPROTEASE INHIBITORS | AMERICAN HOME PRODUCTS CORPORATION | 2002-10-08 | — | — | US | disclosed |
| EP-0780386-B1 | Matrix metalloprotease inhibitors | HOFFMANN LA ROCHE (CH) | 2002-10-02 | — | — | EP | disclosed |
| US-6444704-B1 | ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS, ANTITUMOR AGENTS | AMERICAN HOME PRODUCTS CORPORATION | 2002-09-03 | — | — | US | disclosed |
| US-6441023-B1 | FOR THERAPY OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-27 | — | — | US | disclosed |
| EP-0970046-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | American Cyanamid Company (US) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999042436-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED-ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
| US-5932595-A | ANTIARTHRITIC AGENT; MULTIPLE SCLEROSIS; OSTEOPOROSIS; RESPIRATORY SYSTEM DISORDERS; SKIN DISORDERS; ANTIULCER AGENT | SYNTEX (U.S.A.) INC. (US) | 1999-08-03 | — | — | US | disclosed |
| WO-1998038163-A1 | N-HYDROXY-2-(ALKYL, ARYL, OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |
| WO-1998037877-A1 | N-HYDROXY-2-(ALKYL, ARYL OR HETEROARYL SULFANYL, SULFINYL OR SULFONYL)-3-SUBSTITUTED ALKYL, ARYL OR HETEROARYLAMIDES AS MATRIX METALLOPROTEINASE INHIBITORS | AMERICAN CYANAMID COMPANY (US) | 1998-09-03 | — | — | WO | disclosed |
| EP-0780386-A1 | Matrix metalloprotease inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1997-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020188120-A1 | N-hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl, or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors | MMP12, ADAM33, MMP2 | LDHA 3332/4885ALDH1A1 3029/4885MEN1 4296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.